Summarized by Masters of Longevity from Longevity Technology.
A news article about a newly approved oral Parkinson’s therapy, explaining its trial evidence, safety profile, and clinical significance.
Key Takeaways
- The FDA approved an oral D1/D5-selective dopamine agonist for Parkinson’s disease called JUVMO (tavapadon).
- In TEMPO-3, JUVMO plus levodopa increased daily on time by 1.7 hours versus 0.6 hours for placebo at week 26.
- Common trial side effects included nausea, dizziness, headache, dyskinesia with levodopa, hallucinations, and impulse control symptoms.
